<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156336</url>
  </required_header>
  <id_info>
    <org_study_id>HIPG-CLIN-2014-01</org_study_id>
    <nct_id>NCT02156336</nct_id>
  </id_info>
  <brief_title>Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizons International Peripheral Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Horizons International Peripheral Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine if patients suffering from diabetic peripheral
      neuropathic pain treated with ranolazine will have a greater reduction in pain compared to
      placebo.

      Hypothesis: From the prior clinical observations, and analgesic efficacy in the preclinical
      animal model of neuropathic pain, the investigators hypothesize that subjects randomized to
      ranolazine will show a greater reduction in diabetic neuropathic pain compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough patients met study criteria for enrollment.
  </why_stopped>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">February 8, 2017</completion_date>
  <primary_completion_date type="Actual">February 8, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fifty percent or greater reduction in the mean Numeric Rating Scale (11-point NRS 0-10) recorded in the subjects' diaries from ranolazine compared to placebo.</measure>
    <time_frame>6 weeks (42 Days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Assessment as measured by SF-36 v2</measure>
    <time_frame>Randomization (Day 0) and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain assessment measured by the Visual Analog Scale</measure>
    <time_frame>Randomization (Day 0), Day 14, Day 28, Day 42, and Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain assessment measured by Short-Form McGill Pain Questionnaire</measure>
    <time_frame>Randomization (Day 0) and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain of patients with arterial ischemia measured by Short-Form McGill Pain Questionnaire</measure>
    <time_frame>Randomization (Day 0), Day 14, Day 28, Day 42, and Day 56</time_frame>
    <description>Pain reduction of ranolazine versus placebo in subjects with diabetic peripheral neuropathic pain (DPNP) and arterial ischemia compared to those with DPNP without arterial ischemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional pain medication</measure>
    <time_frame>Randomization (Day 0), Day 14, Day 28, Day 42, and Day 56</time_frame>
    <description>Additional pain medication after the baseline visit as needed for pain reduction in addition to the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events after randomization</measure>
    <time_frame>56 Days</time_frame>
    <description>The rates and severity of Adverse Events (AEs) from Randomization (Day 0) through Termination (Day 56)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Serious Adverse Events after randomization</measure>
    <time_frame>56 Days</time_frame>
    <description>A serious adverse event (SAE), also may be called a serious adverse drug reaction, is any untoward medical occurrence that at any dose:
results in death,
is life-threatening,
requires inpatient hospitalization or prolongation of existing hospitalization,
results in persistent or significant disability/incapacity, or
is a congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Diabetic Peripheral Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>500 mg PLACEBO PO 2 times a day for 1 week (Week 1)
1000 mg PLACEBO PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RANOLAZINE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg RANOLAZINE PO 2 times a day for 1 week (Week 1)
1000 mg RANOLAZINE PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Oral administration, BID; for a maximum of 51 days.</description>
    <arm_group_label>RANOLAZINE</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration, BID; for a maximum of 51 days.</description>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A minimum of 18 years of age;

          2. Provided signed Informed Consent Form and Health Insurance Portability and
             Accountability Act (HIPAA) authorization for this study approved by the Institutional
             Review Board;

          3. Patients must have diabetic peripheral neuropathic pain rated at an average level of
             six (6) or above as documented in daily diary prior to baseline visit and noted at
             Baseline Visit;

          4. Diabetic on a stable insulin regimen or oral medication regimen as determined by the
             investigator [It is recommended Hba1c &lt; 9.5%, making a note that lab normal values may
             vary among sites.];

          5. Clinical Exam Results:

               1. 5.07 Semmes-Weinstein Monofilament Test Subject does not sense monofilament or
                  evokes an abnormal response in a minimum of two (2) out of five (5) test
                  locations on the plantar surface of the foot.

               2. Pin Prick Test Subject experiences allodynia, hyperalgesia, or sensory loss in
                  two (2) out of five (5) test locations in the plantar surface - four (4) and
                  dorsum - one (1) of the foot.

          6. Willing and able to comply with the requirements of the protocol and follow directions
             from the clinic and research staff;

          7. For female patients only:

               -  Be post-menopausal (no menses for at least 2 years) or sterilized,

               -  If subject of childbearing potential, not breastfeeding, has a negative pregnancy
                  test at Baseline (pre-randomization, Day 0), has no intention of becoming
                  pregnant during the course of the study, and is using one or more of the
                  following contraceptive measures:

                    1. Stable regimen of hormonal contraception

                    2. Intra-uterine device

                    3. Condoms with spermicide

                    4. Diaphragm with spermicide

        Exclusion Criteria:

          1. History of allergy or intolerance to ranolazine;

          2. Any condition or concomitant medication that would preclude the safe use of ranolazine
             as outlined in the prescribing information sheet;

          3. In the judgment of the investigator, any clinically-significant ongoing medical
             condition that might jeopardize the patient's safety or interfere with the absorption,
             distribution, metabolism or excretion of the study drug;

          4. In the judgment of the investigator, clinically-significant abnormal physical findings
             during screening (excluding the patient's peripheral neuropathy condition);

          5. Use participation in another experimental or investigational drug or device trial;

          6. Pregnant or breast feeding;

          7. Cirrhosis of the liver;

          8. Psychological or addictive disorders (not limited to, but including for example, drug
             and/or alcohol dependency) that may preclude patient consent or compliance, or that
             may confound study interpretation;

          9. Taking a moderate or strong CYP3A inhibitor (e.g. diltiazem, verapamil, ketoconazole,
             itraconazole, clarithromycin, erythromycin, nefazodone, nelfinavir, ritonavir,
             indinavir, and saquinavir);

         10. Taking inducers of Cytochrome P450, family 3, subfamily A (CYP3A) (e.g. rifampin,
             rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort);

         11. Renal impairment as defined by a calculated serum creatinine clearance of &lt; 30ml/min;

         12. Lower back disorders where symptoms present similarly to DPNP;

         13. Family history of long QT syndrome;

         14. Congenital long QT syndrome;

         15. Subjects taking tricyclic antidepressants;

         16. Subjects taking anti-psychotic drugs;

         17. Patient is taking &gt; 850mg metformin BID;

         18. Any subjects currently taking pregabalin;

         19. Any subjects currently taking gabapentin;

         20. Any subject currently taking MetanxÂ®;

         21. Any subjects currently taking continuous long-term narcotics;

         22. Grapefruit and grapefruit containing products;

         23. Use of P-gp inhibitors - cyclosporine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig M Walker, MD FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute of the South</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Associates</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gould HJ 3rd, Garrett C, Donahue RR, Paul D, Diamond I, Taylor BK. Ranolazine attenuates behavioral signs of neuropathic pain. Behav Pharmacol. 2009 Dec;20(8):755-8. doi: 10.1097/FBP.0b013e3283323c90.</citation>
    <PMID>19773645</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Peripheral Neuropathic Pain</keyword>
  <keyword>Ranexa</keyword>
  <keyword>Ranolazine</keyword>
  <keyword>Neurology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

